Beam Therapeutics Inc. (BEAM)
NASDAQ: BEAM · Real-Time Price · USD
18.05
-0.19 (-1.04%)
May 13, 2025, 4:00 PM - Market closed
Beam Therapeutics Revenue
Beam Therapeutics had revenue of $7.47M in the quarter ending March 31, 2025, with 0.81% growth. This brings the company's revenue in the last twelve months to $63.58M, down -82.38% year-over-year. In the year 2024, Beam Therapeutics had annual revenue of $63.52M, down -83.18%.
Revenue (ttm)
$63.58M
Revenue Growth
-82.38%
P/S Ratio
23.81
Revenue / Employee
$131,631
Employees
483
Market Cap
1.76B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
BEAM News
- 1 day ago - Beam Therapeutics to Participate in 2025 RBC Capital Markets Global Healthcare Conference - GlobeNewsWire
- 1 day ago - Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) - GlobeNewsWire
- 8 days ago - Beam Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewsWire
- 5 weeks ago - Beam Therapeutics Presents Additional Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at 2025 Alpha-1 Foundation 7th Global Research Conference and 10th Patient Congress - GlobeNewsWire
- 6 weeks ago - Biotech stocks plunge as FDA's Peter Marks resigns over RFK Jr. dispute, Moderna and Beam Therapeutics hit hard - Invezz
- 6 weeks ago - Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) by the United States (U.S.) Food and Drug Administration - GlobeNewsWire
- 7 weeks ago - Upgrading Beam Therapeutics: Promising BEAM-302 Data Opens Door For Durable Gene Therapy - Seeking Alpha
- 2 months ago - Gene Edit Biotech Beam Therapeutics Touts Encouraging Data From Early-Stage Gene Therapy Study In Genetic Disorder, Raises $500 Million Via Equity - Benzinga